Cellect Biotechnology Ltd. was founded in 2011 by Dr. Shai Yarkoni and Dr. Nadir Askenasy with a vision of becoming a world leader in regenerative medicine through the development of products facilitating immune stem cell selection.

The Company’s platform technology is based on the game changing perception that stem-cells functional properties rather than appearance should be used to develop superior identification, selection and utilization of stem cells.

The Company’s first product is designed to harness the critical function of sensitivity to specific apoptosis-agents. While these molecules induce apoptosis (programmed cell death) in mature cells, they spare stem-cells. This differential sensitivity is used to dramatically improve the outcome of bone marrow transplantation mainly by elimination of the severe adverse effects while suggesting significant reduction in costs of treatment.

Cellect has established proof of concept for its technology in animals, and has built a comprehensive IP portfolio protecting its development. The Company is now initiating formal preclinical trials for its first product, and is working on the development of its pipeline.

Contact Cellect Biotherapeutics Ltd.
+972-9-974-1444
info@cellectbio.com
Visit Website